IC
NBIX icon

IEQ Capital’s Neurocrine Biosciences NBIX Stock Holding History

IEQ Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$108M Sell
640,304
-125,678
-16% -$18.6M 0.5% 32
2026
Q1 		$101M Buy
765,982
+20,869
+3% +$2.77M 0.47% 35
2025
Q4 		$106M Buy
745,113
+52,512
+8% +$7.61M 0.32% 29
2025
Q3 		$97.2M Buy
692,601
+119,628
+21% +$16.2M 0.3% 31
2025
Q2 		$72M Buy
572,973
+35,956
+7% +$4.12M 0.44% 32
2025
Q1 		$59.4M Sell
537,017
-20,887
-4% -$2.65M 0.47% 32
2024
Q4 		$76.2M Buy
557,904
+45,424
+9% +$5.62M 0.74% 22
2024
Q3 		$59M Buy
512,480
+6,394
+1% +$877K 0.72% 26
2024
Q2 		$69.7M Sell
506,086
-27
-0% -$3.7K 0.94% 19
2024
Q1 		$69.8M Buy
506,113
+23,287
+5% +$3.18M 1% 19
2023
Q4 		$63.6M Buy
482,826
+1,528
+0.3% +$176K 1.06% 18
2023
Q3 		$54.1M Buy
481,298
+30
+0% +$3.16K 1.1% 17
2023
Q2 		$45.4M Buy
+481,268
New +$47M 0.92% 20

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IEQ Capital's NBIX Position: Q2 2026 in Review

IEQ Capital reduced its Neurocrine Biosciences (NBIX) stake by 16% in Q2 2026, selling an estimated $18.6M and leaving 640,304 shares worth $108M. The position accounts for 0.5% of the portfolio, ranked #32.

IEQ Capital first reported a position in NBIX in Q2 2023 and has held it in 13 quarters since. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • IEQ Capital held 640,304 shares of Neurocrine Biosciences worth $108M as of Q2 2026.
  • IEQ Capital sold 125,678 Neurocrine Biosciences shares in Q2 2026, an estimated $18.6M.
  • Neurocrine Biosciences made up 0.5% of IEQ Capital's portfolio in Q2 2026, its #32 holding.
  • IEQ Capital first reported a position in Neurocrine Biosciences in Q2 2023 and has held it in 13 quarters since.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on IEQ Capital's 13F filing for Q2 2026, filed 11 Aug 2026.